Manufacturing of an Individualized Cancer Vaccine based on Modified Vaccinia Ankara (MVA) Viral Platform
2:30 pm - Tuesday 18th November 2025
• Developing the viral-based individualized neoantigen therapeutic vaccine platform myvac from phase I clinical trial to a robust Manufacturing
• Regulatory considerations for personalized cancer vaccines